Exciting Additions to the Board at Century Therapeutics
CENTURY THERAPEUTICS, INC. (NASDAQ: IPSC), a pioneering biotechnology firm focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for serious health challenges such as autoimmune disorders and cancer, is thrilled to announce the appointments of two distinguished leaders, Dr. Han Lee and Dr. Martin Murphy, to its Board of Directors.
Why These Appointments Matter
With Dr. Lee taking up a role on the Audit and Compensation Committees and Dr. Murphy joining the Compensation and Nominating and Corporate Governance Committees, their expertise comes at a critical junction for Century Therapeutics. Their insights will be invaluable as the company works to advance its leading iPSC-derived cell therapy candidates, including CNTY-813. This candidate is being explored as a potentially life-changing, off-the-shelf treatment option for individuals suffering from type 1 diabetes.
Words from the CEO
Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, shared his enthusiasm about the new board members, stating, “Bringing Dr. Lee and Dr. Murphy into our fold at this pivotal moment showcases our commitment to innovation and operational excellence. Their extensive backgrounds in capital formation and corporate development will help steer our strategy as we aim to transition our groundbreaking therapies from a research setting to clinical environments, ultimately benefiting patients and enhancing shareholder value.”
Profiles of the New Board Members
Dr. Han Lee brings a wealth of experience to Century Therapeutics. Previously, he served as the President and Chief Financial Officer of ImmPACT Bio, Inc., a clinical-stage biotechnology entity that was acquired by Lyell Immunopharma. His impressive journey also includes pivotal roles at Neogene Therapeutics and Arcellx. Dr. Lee holds a Ph.D. in genetics and an M.B.A. from Yale University, as well as a B.A. in molecular cell biology from the University of California, Berkeley.
Dr. Murphy's Accomplishments
Dr. Martin Murphy holds significant positions on various boards, including Synairgen plc and Cora Biosciences Limited. Known for co-founding Syncona Limited, he has an extensive background in life sciences and has held key roles at prestigious firms like MVM Life Science Partners and McKinsey & Company. His academic credentials include a Ph.D. from the University of Cambridge and an M.A. in biochemistry from the University of Oxford, underscoring his rich expertise in the field.
About Century Therapeutics
Century Therapeutics stands at the forefront of biotechnological advancement with a rich pipeline of therapies derived from its proprietary iPSC cell line. The company is committed to leveraging its innovative immune evasion engineering technology, Allo-Evasion™, to craft therapies that aim to be accessible and superior to existing treatment options. With their focus on off-the-shelf therapies, they hope to significantly improve patient access and outcomes in treating complex diseases.
Frequently Asked Questions
What is the significance of the appointments of Dr. Han Lee and Dr. Martin Murphy?
Their vast experience in biotechnology and strategic guidance is expected to enhance the company's operations as it advances its therapy development.
What does CNTY-813 target?
CNTY-813 is being developed as a potential off-the-shelf treatment for type 1 diabetes, showcasing Century’s innovative approach to addressing complex health issues.
How is Century Therapeutics innovating in the biotech space?
The company utilizes iPSC-derived therapies and its proprietary Allo-Evasion™ technology to create cell therapies designed for better patient access and effectiveness.
What are the academic backgrounds of the new appointees?
Dr. Han Lee earned a Ph.D. and M.B.A. from Yale and a B.A. from UC Berkeley, while Dr. Martin Murphy holds a Ph.D. from Cambridge and an M.A. from Oxford.
How can we learn more about Century Therapeutics?
Visit Century Therapeutics’ website or connect with them on LinkedIn for the latest updates and information about their developing therapies.
